Skip to main navigation Skip to search Skip to main content

Neurosurgeons’ perspective on surgical treatment of glioblastoma: practices, beliefs and willingness to randomize in surgical trials

  • Johnny Duerinck
  • , Louise Lescrauwaet
  • , Philipp Karschnia
  • , Rebeca Pérez Alfayate
  • , Michael D. Jenkinson
  • , Eric Suero Molina
  • , Matthias Simon
  • , Jasper Gerritsen
  • , Jorn Van Der Veken
  • , Thiebaud Picart
  • , Emilie Le Rhun
  • , Giuseppe Minniti
  • , Matthias Preusser
  • , Michael Weller
  • , Mandy Melissa Jane Wittens
  • , Asgeir S. Jakola
  • , Alireza Mansouri

Research output: Contribution to journal › Article › peer-review

7 Downloads (Pure)

Abstract

Background: The optimal extent of resection for glioblastoma remains debated, with high-level evidence from randomized controlled trials (RCTs) notably scarce. We aimed to evaluate international surgical practices, perceived quality of evidence, and feasibility of future RCTs through an international survey of neurosurgeons.

Methods: An international survey was distributed via European Organization for Research and Treatment of Cancer (EORTC), European Association of Neurosurgical Societies (EANS), Congress of Neurological Surgeons (CNS), and national societies. We used descriptive statistics to summarize surgical practices and univariate analysis and multivariate regression to identify demographic or institutional factors associated with clinical decision-making.

Results: Responses were received from 328 neurosurgeons across 38 countries. Participation was predominantly from Europe (81.1%), with 12.2% from North America. Most participants (82.9%) practiced in academic centers. While 60.4% identified supramarginal resection (SMR) as the optimal surgical goal, 37.8% aim for complete resection of enhancing tumor (CRET). Overall, 90.2% viewed the evidence for CRET as strong, compared to 63.1% for SMR. Despite these views, 72.6% expressed willingness to randomize patients between CRET and SMR, while 49.4% would be willing to randomize between partial resection and biopsy, if CRET is not feasible. Despite differences in individual practice, willingness to participate in RCTs remained consistent across geographic regions. The incomplete overlap between case-based decisions and general willingness to randomize highlights the importance of case-specific nuances. A paradox was observed where perceived weak evidence correlated with lower willingness to randomize(P < .001).

Conclusion: There is substantial global willingness among neurosurgeons to participate in surgical RCTs for glioblastoma. These findings provide a foundation for designing future international trials to resolve long-standing controversies regarding optimal surgical strategy for glioblastoma.
Original languageEnglish
Article numbervdag166
Pages (from-to)1-14
Number of pages14
JournalNeuro-Oncology Advances
Volume8
Issue number1
DOIs
Publication statusPublished - 12 Jan 2026

Bibliographical note

Copyright the Author(s) 2026. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

  • clinical equipoise
  • extent of resection (EOR)
  • glioblastoma
  • supramarginal resection
  • surgical randomized controlled trials (RCTs)

Fingerprint

Dive into the research topics of 'Neurosurgeons’ perspective on surgical treatment of glioblastoma: practices, beliefs and willingness to randomize in surgical trials'. Together they form a unique fingerprint.

Cite this